{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 451555899
| IUPAC_name = 2-(Dimethylamino)ethyl (2-ethylbutoxy)diphenylacetate
| image = Denaverin.svg

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|denaverine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = Gr 1 (Germany)
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx
| routes_of_administration = [[intramuscular injection]], [[suppositories]]

<!--Pharmacokinetic data-->
| bioavailability = 8% ([[suppositories]]),<br />37% (oral solution)
| protein_bound =  
| metabolism = mainly [[hepatic]], at least 11 metabolites
| elimination_half-life = 34 hours
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 3579-62-2
| CAS_supplemental = <br />{{CAS|3321-06-0}} ([[hydrochloride]])
| ATCvet = yes
| ATC_prefix = G02
| ATC_suffix = CX90
| ATC_supplemental =  
| PubChem = 71130
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1614656
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = O14NF38MTL
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07787
| synonyms =  
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 64278

<!--Chemical data-->
| chemical_formula =  
| C=24 | H=33 | N=1 | O=3 
| molecular_weight = 383.52 g/mol
| smiles            = CCC(CC)COC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCCN(C)C
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C24H33NO3/c1-5-20(6-2)19-28-24(21-13-9-7-10-14-21,22-15-11-8-12-16-22)23(26)27-18-17-25(3)4/h7-16,20H,5-6,17-19H2,1-4H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = FPTOUQZVCUIPHY-UHFFFAOYSA-N
}}
'''Denaverine''' is an [[antispasmodic]] drug. It was developed in Germany and patented in 1974. '''Denaverine  hydrochloride''' is used in veterinary medicine under the trade name '''Sensiblex''' as a muscle relaxant for the [[myometrium]] of cows and dogs during childbirth.<ref>[http://www.ema.europa.eu/pdfs/vet/mrls/030797en.pdf Committee for Veterinary Medicinal Products: Denavering Hydrochloride Summary Report]</ref> Under the trade name '''Spasmalgan''', it has also been used in humans for the treatment of [[urogenital]] and [[gastrointestinal]] spasms.<ref>{{cite book|title=Rote Liste|editor1-first=H|editor1-last=Dootz|editor2-first=A|editor2-last=Kuhlmann|editor3-first=K|editor3-last=Hoffmann|at=77&nbsp;023|edition=2005|isbn=3-87193-306-6|publisher=Editio Cantor|location=Aulendorf|language=German}}</ref>

==Mechanism of action==
Denaverine, like [[papaverine]], acts as a [[phosphodiesterase inhibitor]]. Additionally, it has [[anticholinergic]] effects.<ref name="Arzneistoff-Profile">{{cite book|title=Arzneistoff-Profile|editor1=Dinnendahl, V |editor2=Fricke, U |publisher=Govi Pharmazeutischer Verlag|location=Eschborn, Germany|date=2010|edition=23|volume=4|isbn=978-3-7741-9846-3|language=German}}</ref>

==References==
{{reflist}}

[[Category:Antispasmodics]]
[[Category:Amines]]
[[Category:Carboxylate esters]]
[[Category:Ethers]]


{{genito-urinary-drug-stub}}